Literature DB >> 16096540

Smoke inhalation enhances early alveolar leukocyte responsiveness to endotoxin.

Mary Jo Wright1, Joseph T Murphy.   

Abstract

BACKGROUND: Pulmonary dysfunction after smoke inhalation and thermal injury is associated with excessive morbidity and mortality. The purpose of this study was to evaluate alveolar leukocyte function after thermal injury and smoke inhalation.
METHODS: Twenty-one patients with thermal injury only (n = 8); thermal injury and smoke inhalation injury (n = 8); and nonburned controls (n = 5) were assessed by means of bronchoscopically directed lavage (bronchoalveolar lavage [BAL]) on the first and fourth days postinjury. BAL-isolated pulmonary leukocytes were assessed for number, composition, viability, and production of tumor necrosis factor (TNF)alpha, interleukin (IL)-8, and IL-6 in response to 100 ng/mL of lipopolysaccharide (LPS) (mean +/- SEM; significance at p < 0.05).
RESULTS: Six of eight Smoke patients had gross evidence of lung injury. On day 1, Smoke and Burn BAL isolates yielded greater cell counts than Control (10.6 vs. 4.5 vs. 2.4 x 10(6)/mL). Smoke macrophages on day 1 produced more TNFalpha (1.2 vs. 0.2 ng/mL), IL-6 (8.0 vs. 1.9 ng/mL), and IL-8 (85 vs. 32 ng/mL) after LPS stimulation compared with respective unstimulated (0 ng/mL of LPS) day-1 Smoke cells. LPS-stimulated Burn cells on day 1 produced more IL-8 (150 vs. 62 ng/mL) but not TNFalpha (0.4 vs. 0.25 ng/mL) or IL-6 (1.8 vs. 0.69 ng/mL), when compared with respective unstimulated Burn cells. By day 4, LPS-stimulated Smoke and Burn cells produced significantly more TNFalpha (Smoke, 0.41 vs. 0.16 ng/mL; Burn, 0.87 vs. 0.51 ng/mL) and IL-6 (Smoke, 2.5 vs. 0.47 ng/mL; Burn, 4.1 vs. 1.47 ng/mL), but not IL-8 (Smoke, 51.1 vs. 51.1 ng/mL; Burn, 54.4 vs. 55.6 ng/mL), compared with respective unstimulated day-4 cells.
CONCLUSION: Smoke inhalation induces a massive influx of alveolar leukocytes that are primed for an early, enhanced LPS-activated cytokine response compared with alveolar leukocytes isolated after burn injury alone or normal controls.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096540     DOI: 10.1097/01.ta.0000171588.25618.87

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  6 in total

1.  The acute pulmonary inflammatory response to the graded severity of smoke inhalation injury.

Authors:  Joslyn M Albright; Christopher S Davis; Melanie D Bird; Luis Ramirez; Hajwa Kim; Ellen L Burnham; Richard L Gamelli; Elizabeth J Kovacs
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

2.  Effects of Multiday Ethanol Intoxication on Postburn Inflammation, Lung Function, and Alveolar Macrophage Phenotype.

Authors:  Brenda J Curtis; Devin M Boe; Jill A Shults; Luis Ramirez; Elizabeth J Kovacs
Journal:  Shock       Date:  2019-05       Impact factor: 3.454

3.  Early pulmonary immune hyporesponsiveness is associated with mortality after burn and smoke inhalation injury.

Authors:  Christopher S Davis; Joslyn M Albright; Stewart R Carter; Luis Ramirez; Hajwa Kim; Richard L Gamelli; Elizabeth J Kovacs
Journal:  J Burn Care Res       Date:  2012 Jan-Feb       Impact factor: 1.845

4.  DNA and inflammatory mediators in bronchoalveolar lavage fluid from children with acute inhalational injuries.

Authors:  Benny L Joyner; Samuel W Jones; Bruce A Cairns; Bradford D Harris; Andrea M Coverstone; Kathleen A Abode; Shiara M Ortiz-Pujols; Keith C Kocis; Terry L Noah
Journal:  J Burn Care Res       Date:  2013 May-Jun       Impact factor: 1.845

5.  CFTR-regulated MAPK/NF-κB signaling in pulmonary inflammation in thermal inhalation injury.

Authors:  Zhi Wei Dong; Jing Chen; Ye Chun Ruan; Tao Zhou; Yu Chen; YaJie Chen; Lai Ling Tsang; Hsiao Chang Chan; Yi Zhi Peng
Journal:  Sci Rep       Date:  2015-10-30       Impact factor: 4.379

6.  Are serum cytokines early predictors for the outcome of burn patients with inhalation injuries who do not survive?

Authors:  Gerd G Gauglitz; Celeste C Finnerty; David N Herndon; Ronald P Mlcak; Marc G Jeschke
Journal:  Crit Care       Date:  2008-06-18       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.